Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.50 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.50 |
| ▸ | MIF | P14174 | 1/20 | 0.48 |
| ▸ | GABRP | O00591 | 1/20 | 0.46 |
| ▸ | GABRD | O14764 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4886683 | 0.80 | ALDH1A1 (0.58) | NAPRTALDH1A1HSD17B10ALOX15KDM4E | |
| SCHEMBL6987829 | 0.79 | NAPRT (0.46) | NAPRTP4HA1P4HTMMIFTP53 | |
| SCHEMBL1735166 | 0.78 | RXRA (0.55) | NAPRTALOX15TSHRTP53 | |
| SCHEMBL1968189 | 0.77 | NNMT (0.50) | NAPRTHSD17B10KDM4ECYP2C19TSHR | |
| SCHEMBL600134 | 0.77 | NAPRT (0.40) | NAPRTALDH1A1HSD17B10ALOX15KDM4E | |
| SCHEMBL27962218 | 0.77 | NAPRT (0.41) | NAPRTALDH1A1HSD17B10ALOX15KDM4E | |
| SCHEMBL665987 | 0.77 | JUN (0.47) | ALDH1A1HPGDTSHRJUNNFKB1 | |
| SCHEMBL185448 | 0.76 | ALDH1A1 (0.54) | NAPRTALDH1A1HSD17B10ALOX15KDM4E | |
| SCHEMBL3705899 | 0.76 | ALDH1A1 (0.54) | NAPRTALDH1A1HSD17B10ALOX15KDM4E | |
| SCHEMBL26987992 | 0.75 | ALDH1A1 (0.58) | ALDH1A1ALOX15HPGDNFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 598 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117700369-A | Preparation method of 2- (2-chloropyrimidine-5-yl) acetic acid/ester | 上海彩迩文生化科技有限公司 | 2024-03-15 | — | — | CN | claimed |
| CN-109467536-B | Synthesis method of 2-chloro/hydroxypyrimidine-5-carboxylic acid | 沧州普瑞东方科技有限公司 | 2020-06-05 | — | — | CN | claimed |
| CN-105683202-B | Boric acid compound | SYNTRIX生物系统公司 | 2019-05-10 | — | — | CN | claimed |
| CN-109467536-A | 2- chlorine/hydroxy pyrimidine -5- carboxylic acid synthetic method | 沧州普瑞东方科技有限公司 | 2019-03-15 | — | — | CN | claimed |
| CN-105683202-A | 2- [5- [ N- (4-fluorophenyl) carbamoyl ] pyrimidin-2-ylmethylsulfanylmethyl ] -4- (trifluoromethoxy) phenyl ] boronic acid | SYNTRIX生物系统公司 | 2016-06-15 | — | — | CN | claimed |
| EP-3027627-A1 | 2- [5- [N- (4 -FLUOROPHENYL) CARBAMOYL]PYRIMIDIN- 2 - YLSULFANYLMETHYL]-4- (TRIFLUOROMET HOXY) PHENYL]BORONIC ACID | Syntrix Biosystems, Inc. (US) | 2016-06-08 | — | — | EP | claimed |
| CN-104844573-A | Miazines BTK inhibitor, preparation method and medical application thereof | UNIV CHINA PHARMA | 2015-08-19 | — | — | CN | claimed |
| US-8969365-B2 | Thiopyrimidinecarboxamides as CXCR1/2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2015-03-03 | — | — | US | claimed |
| US-20150038461-A1 | THIOPYRIMIDINECARBOXAMIDES AS CXCR1/2 MODULATORS | SYNTRIX BIOSYSTEMS, INC. (US) | 2015-02-05 | — | — | US | claimed |
| WO-2015016938-A1 | 2- [5- [N- (4 -FLUOROPHENYL) CARBAMOYL] PYRIMIDIN- 2 - YLSULFANYLMETHYL] -4- (TRIFLUOROMET HOXY) PHENYL] BORONIC ACID | SYNTRIX BIOSYSTEMS, INC. (US) | 2015-02-05 | — | — | WO | claimed |
| CN-103664796-A | Synthesis method of 5-[2-(5-carboxyl-pyrimidyl)]-1,3-benzene dicarboxylic acid | UNIV LIAONING NORMAL | 2014-03-26 | — | — | CN | claimed |
| CN-116406355-B | P38 alpha mitogen-activated protein kinase inhibitors | GEN1E生命科学公司 | 2026-05-15 | — | — | CN | disclosed |
| WO-2026087442-A1 | AMINO-IMIDAZOLE ANTIBACTERIAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| EP-4100410-B1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES INC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4540267-B1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2006049681-A2 | SELECTIVE NEUROPEPTIDE Y2 RECEPTOR AGONISTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006048297-A1 | PROCESS FOR THE PRODUCTION OF PYRIMIDINE-5-CARBOXYLATES | LONZA AG (CH) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006018284-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | NOVARTIS AG (CH) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006010750-A1 | SUBSTITUTED INDOLYL ALKYL AMINO DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-02 | — | — | WO | disclosed |
| CN-1549717-A | Cysteine protease inhibitors having 2-cyano-4-aminopyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammation and other diseases | ��˹��ŵ�� | 2004-11-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038461-A1 | THIOPYRIMIDINECARBOXAMIDES AS CXCR1/2 MODULATORS | CXCR1, CXCR5, CXCR2 | NAPRT 491/4885ALDH1A1 1648/4885HSD17B10 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.